Objective
To compare 1-dimensional (1D) and 3-dimensional (3D) volume measurements and determine
whether primary tumor (PT) burden is predictive of overall survival (OS) following
cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC).
Materials and Methods
Records and imaging studies of patients with mRCC treated with CN from 2006 to 2015
were included, with tumor volumes measured by a faculty radiologist blinded to clinical
outcomes using Advantage Workstation Volume Share (Ver 4.6, GE, Waukesha, WI).
Results
Complete PT and metastatic tumor volumes were measured for 67 patients. For 15 (22.3%)
patients, 1D volume was within ±10% of the measured 3D volume. In 40 (59.7%) patients,
the 1D calculated PT volume was >10% of the actual 3D volume.
Fractional percentage of tumor volume (FPTV) removed during CN was calculated using
the formula PT volume/(PT + met volume). FPTV was not associated with OS when analyzed
as a continuous variable.
Patients were divided into 2 groups based on previously published cut point of 90%
FPTV. No differences between cohorts in age, gender, grade, subtype, number of metastatic
sites, performance status, Memorial Sloan Kettering Cancer Center risk group, or International
Metastatic Renal Cell Carcinoma Database Consortium risk group were identified. OS
was not different between cohorts (P = .38).
Conclusion
1D measurements of PT diameter frequently overestimate mRCC PT volume. In patients
with mRCC selected for CN, the ratio of primary to metastatic tumor does not predict
OS.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.N Engl J Med. 2001; 345: 1655-1659
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.Lancet. 2001; 358: 966-970
- The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.J Urol. 2011; 185: 60-66
- Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.Eur Urol. 2014; 66: 704-710
- Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.Nat Rev Urol. 2009; 6: 375-383
- Surgery for metastatic renal cell carcinoma.J Urol. 1967; 97: 973-977
- Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.J Urol. 1990; 144 (discussion 617-618): 614-617
- Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.J Urol. 1997; 158: 1691-1695
- Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.BJU Int. 2007; 100: 755-759
- Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.BJU Int. 2010; 106: 1266-1269
- New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst. 2000; 92: 205-216
- Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study.Abdom Imaging. 2014; 39: 488-496
- Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.J Clin Oncol. 1999; 17: 2530-2540
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol. 2009; 27: 5794-5799
- Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?.Cancer. 2010; 116: 3378-3388
- Comparison of 1D, 2D, and 3D nodule sizing methods by radiologists for spherical and complex nodules on thoracic CT phantom images.Acad Radiol. 2014; 21: 30-40
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.Lancet Oncol. 2013; 14: 141-148
- Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med. 2015; 373: 1803-1813
- Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?.Clin Cancer Res. 2007; 13: 693s-696s
- Checkpoint modulation—a new way to direct the immune system against renal cell carcinoma.Hum Vaccin Immunother. 2015; 11: 1201-1208
- Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.Urol Oncol. 2016; 34 (e7-e13): 258
Article info
Publication history
Published online: September 22, 2016
Accepted:
September 8,
2016
Received:
July 8,
2016
Footnotes
Financial Disclosure: The authors declare that they have no relevant financial interests.
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
